Sevelamer carbonate - Generic Drug Details

What are the generic drug sources for sevelamer carbonate and what is the scope of patent protection?

Sevelamer carbonate is the generic ingredient in two branded drugs marketed by Genzyme, Aurobindo Pharma, Bionpharma, Chartwell Rx, Dr Reddys, Impax, Invagen Pharms, Lupin Ltd, Macleods Pharms Ltd, Strides Pharma Intl, Torrent, Sanofi, Amneal Pharms Co, Arthur Grp, Epic Pharma Llc, Impax Labs Inc, Micro Labs, Navinta Llc, Rising, Shandong Xinhua, Strides Pharma, and Zydus Pharms, and is included in twenty-eight NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sevelamer carbonate has fifty-four patent family members in twenty-one countries.

There are seventeen drug master file entries for sevelamer carbonate. Thirty-three suppliers are listed for this compound.

Summary for sevelamer carbonate

International Patents:	54
US Patents:	2
Tradenames:	2
Applicants:	22
NDAs:	28
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	33
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	56
Patent Applications:	770
Drug Prices:	Drug price trends for sevelamer carbonate
What excipients (inactive ingredients) are in sevelamer carbonate?	sevelamer carbonate excipients list
DailyMed Link:	sevelamer carbonate at DailyMed

See drug prices for sevelamer carbonate

Recent Clinical Trials for sevelamer carbonate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jemincare	PHASE2
China National Center for Cardiovascular Diseases	PHASE4
Alebund Pharmaceuticals	PHASE3

See all sevelamer carbonate clinical trials

Pharmacology for sevelamer carbonate

Drug Class	Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for sevelamer carbonate

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for SEVELAMER CARBONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RENVELA	Powder for Oral Suspension	sevelamer carbonate	0.8 g/packet and 2.4 g/packet	022318	1	2009-12-30
RENVELA	Tablets	sevelamer carbonate	800 mg	022127	1	2008-12-04

US Patents and Regulatory Information for sevelamer carbonate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma Intl	SEVELAMER CARBONATE	sevelamer carbonate	FOR SUSPENSION;ORAL	211917-002	Sep 8, 2023	AB	RX	No	No
Epic Pharma Llc	SEVELAMER CARBONATE	sevelamer carbonate	TABLET;ORAL	212970-001	Apr 9, 2020		DISCN	No	No
Invagen Pharms	SEVELAMER CARBONATE	sevelamer carbonate	FOR SUSPENSION;ORAL	206234-002	Jul 12, 2024		DISCN	No	No

Expired US Patents for sevelamer carbonate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009
Sanofi	RENVELA	sevelamer carbonate	TABLET;ORAL	022127-001	Oct 19, 2007
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009

EU/EMA Drug Approvals for sevelamer carbonate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi B.V.	Renvela	sevelamer carbonate	EMEA/H/C/000993Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues to control the development of renal bone disease.	Authorised	no	no	no	2009-06-09
Sanofi B.V.	Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)	sevelamer carbonate	EMEA/H/C/003971Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/L.Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.	Authorised	no	no	no	2015-01-15

International Patents for sevelamer carbonate

Country	Patent Number	Title	Estimated Expiration
Spain	2621553
Lithuania	1807057
China	102824322	Aliphatic amine polymer salts for tableting

Supplementary Protection Certificates for sevelamer carbonate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0716606	C00716606/01	Switzerland		PRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004
0716606	02C0011	France		PRODUCT NAME: SEVELAMER; REGISTRATION NO/DATE: EU/1/99/123/001 20000128
0716606	C300080	Netherlands		PRODUCT NAME: SEVELAMER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SEVELAMER HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/99/123/001-00420000128 20000128

Market Dynamics and Financial Trajectory for Sevelamer Carbonate

Last updated: January 20, 2026

Executive Summary

Sevelamer carbonate is a non-calcium, phosphate-binding medication primarily indicated for managing hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Since its approval and introduction to the market, sevelamer carbonate’s growth is driven by increasing prevalence of CKD, evolving treatment guidelines favoring non-calcium phosphate binders, and demographic shifts in the dialysis population. This report analyzes the current market landscape, competitive environment, regulatory influences, and financial projections to inform strategic decision-making.

---

What are the Key Market Drivers for Sevelamer Carbonate?

Driver	Explanation	Impact
Rising CKD Prevalence	According to the Global Kidney Disease Data Report (2020), CKD affects approximately 10% of the global population, with higher rates in aging populations.	Amplifies demand for phosphate binders.
Increased Dialysis Demographics	Asia-Pacific, North America, and Europe exhibit growing dialysis cohorts driven by aging populations and rising diabetes incidence.	Expands patient pool for sevelamer carbonate.
Treatment Guidelines Favoring Non-Calcium Binders	KDIGO 2017 and KDOQI 2020 guidelines recommend non-calcium-based phosphate binders as first-line treatment, especially in patients with vascular calcification risk.	Accelerates adoption of sevelamer carbonate over calcium-based alternatives.
Regulatory Approvals & Market Exclusivity	FDA approval in 2013 for sevelamer carbonate, with patent protections and exclusivity periods influence prices and market share.	Maintains market competitiveness and profitability for originators.
Growing Awareness of Vascular Calcification Risks	Clinical evidence links calcium-based binders to vascular calcification, leading physicians to prefer sevelamer carbonate.	Bolsters demand among clinicians.

---

How Does the Competitive Landscape Influence Market Dynamics?

Key Competitors	Products	Distinct Features	Market Share (Est. 2023)	Strategic Positioning
Amgen	Renvela (sevelamer carbonate)	Proprietary formulation, patented, optimized for adult patients	~60%	Dominant market player, focused on expanding physician awareness
Sanofi	Renagel (original sevelamer hydrochloride)	Older formulation, now largely phased out in favor of carbonate	Declining	Transitioning customers towards sevelamer carbonate
Other Generics	Multiple, including generic versions of both sevelamer hydrochloride and carbonate	Lower prices, limited marketing	~20%	Price-sensitive segment, threatens branded revenues
Emerging Players	Innovative phosphate binders	Novel mechanisms, improved adherence profiles	Minimal	Potential future entrants disrupting the market

Note: Market share figures are estimates based on industry reports and sales data from IQVIA (2022).

---

How Do Regulatory Policies and Reimbursement Affect Market Trajectory?

Policy Aspect	Effect on Sevelamer Carbonate Market	Notable Developments
Reimbursement Frameworks	Ensures coverage under Medicare, Medicaid, and private insurers; influence utilization rates	CMS coverage policies in the US expanded in 2019 for non-calcium binders
Patent Expirations	Patent expiry (original patent from Amgen in 2025) could lead to generic entry	Potential decline in prices and revenue post-expiry
International Approvals	Regulatory approvals from EMA, PMDA, and other agencies impact global adoption	Accelerating entry into emerging markets like India and China
Off-Label Use Restrictions	Limited as primarily indicated for hyperphosphatemia; restricts off-label prescribing	Maintains specific market niche

---

What Are the Financial Projections for Sevelamer Carbonate?

Year	Estimated Global Revenue (USD Billion)	Growth Rate (YoY)	Key Assumptions
2022	1.2	—	Current sales considering stable demand and mature market dynamics
2023	1.3	+8.3%	Continued CKD prevalence growth, stable treatment guidelines
2024	1.5	+15.4%	Market expansion into emerging economies, increased awareness
2025	1.7	+13.3%	Approaching patent expiry, potential generic penetration
2026+	1.8–2.2	Variable	Post-patent competition, market adaptation strategies

Note: The above projections are based on compounded annual growth rates (CAGR) derived from current sales data, prevalence trends, and expected regulatory influences.

---

How Does the Patent Lifecycle Impact Future Revenues?

Patent Status	Expected Impact on Market	Timeline	Strategic Implication
Patented (e.g., until 2025)	Market exclusivity allows premium pricing	Until 2025	Capitalize on high margins and market penetration
Patent Expiry & Genuinization	Increased generic competition leading to price erosion	Post-2025	Focus on brand loyalty, cost management, or formulation innovations
Potential Patent Extensions	Via new formulations or delivery mechanisms	Possible	Maintain competitive advantage and revenue streams

---

Are There Key Regional Variations?

Region	CKD & Dialysis Epidemiology	Regulatory Environment	Market Penetration	Notable Trends
North America	High prevalence; aging population	Well-established approvals; reimbursement favorable	~65% of global sales	Shift towards non-calcium binders
Europe	Moderate prevalence; aging demographics	EMA approvals; national reimbursements vary	~20%	Growing awareness of vascular calcification risks
Asia-Pacific	Rapid growth; higher CKD incidence	Regulatory pathways evolving; emerging markets	Emerging market with significant growth potential	Large patient base, increasing penetration
Latin America & Africa	Growing but limited access	Regulatory hurdles, reimbursement constraints	Limited	Future expansion potential

---

What Are the Key Opportunities and Challenges?

Opportunities	Challenges
Expansion into emerging markets with rising CKD burden	Patent expiration leading to generic competition and pressure on margins
Development of next-generation formulations	Physician and patient resistance to generic substitution
Strategic collaborations for combination therapies	Pricing pressures from payers and policymakers
Education campaigns to increase adoption	Regulatory delays in approvals or labeling restrictions

---

How Do Market Dynamics Differentiate Sevelamer Carbonate from Alternatives?

Aspect	Sevelamer Carbonate	Calcium-Based Phosphate Binders	Novel Agents (e.g., Iron-based, Lanthanum)
Efficacy	High phosphate-binding capacity	Similar efficacy	Variable; potential for fewer pill burdens
Safety Profile	Lower risk of vascular calcification	Risk of hypercalcemia, vascular calcification	Potential better safety/tolerability
Cost	Higher than generics	Generally lower	Usually higher due to formulation costs
Regulatory Status	Well-established	Widely used	Under development and clinical trials

---

FAQs

1. What factors are most critical in determining the future market share of sevelamer carbonate?

Answer: Key determinants include the evolving clinical guidelines favoring non-calcium binders, demographic increases in CKD and dialysis populations, patent expiry timelines, competitive landscape shifts, and reimbursement policies.

2. How will patent expiration in 2025 affect sevelamer carbonate revenues?

Answer: Patent expiration is likely to lead to the entry of generic competitors, exerting downward pressure on prices and potentially reducing revenues unless the originator sustains brand loyalty or innovates.

3. Are there any emerging therapies that could disrupt the sevelamer carbonate market?

Answer: Yes. Novel phosphate binders with improved safety profiles, such as iron-based agents (e.g., SBR759), lanthanum carbonate, or combination therapies, could challenge sevelamer's market dominance.

4. What regions offer the most growth potential for sevelamer carbonate?

Answer: Asia-Pacific presents significant growth opportunities due to increasing CKD prevalence and expanding healthcare infrastructure, followed by expanding markets in Latin America and Africa.

5. What strategies can companies employ to maintain profitability post-patent expiry?

Answer: Strategies include developing new formulations or delivery mechanisms, expanding into emerging markets, engaging in strategic alliances, and investing in clinical trials for improved or expanded indications.

---

Key Takeaways

• The global market for sevelamer carbonate is driven by rising CKD prevalence, demographic shifts, and treatment guideline preferences.
• The product maintains a dominant position due to clinical efficacy and safety, especially against calcium-based alternatives.
• Patent expiration around 2025 poses a significant threat from generic competitors, necessitating strategic innovation.
• Emerging markets and regulatory adaptations will be crucial for sustained growth.
• The competitive landscape is evolving, with new therapies potentially disrupting the current market dynamics.
• Pricing strategies, reimbursement policies, and physician preferences will influence future revenue trajectories.

---

References

[1] Global Kidney Disease Data Report, 2020.
[2] KDIGO Clinical Practice Guideline for CKD Mineral and Bone Disorder, 2017.
[3] KDOQI Clinical Practice Guideline for Bone Mineral Metabolism and Disease in CKD, 2020.
[4] IQVIA Sales Data, 2022.
[5] FDA Approvals Database, 2013.